Intrinsic cardiac adrenergic cells contribute to LPS-induced myocardial dysfunction
Communications Biology, 2022 Yang et al report that intrinsic cardiac adrenergic cell-derived norepinephrine promotes myocardial dysfunction in response to LPS. They demonstrate norepinephrine produced by these cells activated β1-adrenergic receptors on cardiomyocytes increasing the
Duomeng Yang +11 more
doaj +1 more source
Clinical and functional characterisation of a novel TNFRSF1A c.605T > A/V173D cleavage site mutation associated with tumour necrosis factor receptor-associated periodic fever syndrome (TRAPS), cardiovascular complications and excellent response to etanercept treatment. [PDF]
, 2008 Objectives: To study the clinical outcome, treatment response, T-cell subsets and functional consequences of a novel tumour necrosis factor (TNF) receptor type 1 (TNFRSF1A) mutation affecting the receptor cleavage site.
B H Belohradsky +7 more
core +1 more source
Journal of Bone and Mineral Research, 2001 Abstract Although tumor necrosis factor receptor-associated factor 6 (TRAF6) is required in receptor activator of NF-κB-receptor activator of NF-κB ligand (RANK-RANKL) signaling for osteoclastogenesis, it has remained unclear whether TRAF6 is crucial in tumor necrosis factor α (TNF-α)-induced osteoclastogenesis.
Kaji, K. +5 more
openaire +2 more sources
The role of the TNF receptors and apoptosis inducing ligands in tumor growth [PDF]
The Ukrainian Biochemical Journal, 2016 Tumor necrosis factor (TNF) superfamily receptors and TNF apoptosis inducing ligands play an important role in the realization of TNF function and control tumor growth.
O. H. Minchenko1 +3 more
doaj +1 more source
How to target apoptosis signaling pathways for the treatment of pediatric cancers [PDF]
, 2013 Apoptosis represents one of the most important forms of cell death in higher organisms and is typically dysregulated in human cancers, including pediatric tumors.
Fulda, Simone
core +2 more sources
Tumor necrosis factor antagonists: structure, function and tuberculosis risks [PDF]
Einstein (São Paulo), 2009 New therapeutic options bring new problems and also new knowledge about disease mechanisms. Ten years ago the first antagonist to tumor necrosis factor was first used to treat inflammatory diseases and the use of anti-cytokines has proved to be a ...
Jacyr Pasternak
doaj
Analytical Cellular Pathology, 2010 Background: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) initiates apoptosis in tumor cells upon binding to its cognate agonistic receptors, death receptors 4 and 5 (DR4 and DR5). The activity of the insulin-like growth factor 1 (IGF-1)
Bodvael Pennarun +5 more
doaj +1 more source
Tumor necrosis factor inhibitors in psoriatic arthritis. [PDF]
, 2017 INTRODUCTION: Psoriatic arthritis (PsA) is a chronic inflammatory disease that can result in significant disability. With the emergence of tumor necrosis factor inhibitors (TNFi), therapeutic outcomes in PsA have improved substantially.
Kraft, Walter K. +2 more
core +2 more sources
Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors
Journal of Experimental Medicine, 1992 The receptors for tumor necrosis factor (TNF) exist in cell-associated as well as soluble forms, both binding specifically to TNF. Since the soluble forms of TNF receptors (sTNF-Rs) can compete with the cell- associated TNF receptors for TNF, it was ...
Dan Aderka +4 more
semanticscholar +1 more source
Nail Lichen Planus: Successful Treatment with Etanercept
Case Reports in Dermatology, 2010 Background: Etanercept is a fully human tumor necrosis factor α receptor fusion protein that binds tumor necrosis factor α with greater affinity than natural receptors.
N. Irla +3 more
doaj +1 more source